Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573806 | 0.95 | MET (0.91) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL29355971 | 0.89 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL93550 | 0.89 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL29394198 | 0.89 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2572767 | 0.89 | MET (0.84) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2570505 | 0.88 | MET (0.80) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL1178807 | 0.88 | MET (0.98) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL3320204 | 0.87 | MET (0.79) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL16324440 | 0.87 | MET (0.80) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2566579 | 0.87 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018383-B1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PROD INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2018383-B1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PROD INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| WO-2007132308-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | MET 2876/4885CYP2C9 3780/4885PDE3B 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.